Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 25,328,649 $ 4,515,398
Accounts receivable - project revenue and reimbursable project costs 10,400
Other receivable from joint venture 521,272
Prepaid expenses and other current assets 121,201 70,067
Deferred financing costs, net 491,168
Total Current Assets 25,971,122 5,087,033
Investment in Joint Venture 671,888
Other Assets    
Patent costs 1,539,881 1,367,692
Deferred financing cost, net 491,268
Total Other Assets 1,539,881 1,858,960
Total Assets 28,182,891 6,945,993
Current Liabilities    
Accounts payable and accrued liabilities 1,389,124 1,151,210
Total Current Liabilities 1,389,124 1,151,210
Total Liabilities 1,389,124 1,151,210
Commitments and Contingencies - Note 5
Stockholders' Equity    
Common stock, $0.001 par value, 100,000,000 authorized, 30,500,935 shares and 12,737,703 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 30,501 12,738
Additional paid-in capital 127,034,386 93,602,539
Accumulated deficit (100,274,600) (87,821,514)
Total Stockholders' Equity 26,793,767 5,794,783
Total Liabilities and Stockholders' Equity 28,182,891 6,945,993
Convertible Series A Preferred Shares    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 813 1,020
Convertible Series B Preferred Shares    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: $ 2,667